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Mild hypoproliferative anemia with abnormal iron metabolism frequently accompanies chronic inflamma-
tion and infection in humans. To determine whether anemia is associated with chronic relapsing arthritis
induced by bacterial cell wall polymers, serial determinations of the hematocrit were measured in rats injected
intraperitoneally with sonicated peptidoglycan-polysaccharide fragments from group A streptococci. Acute
anemia peaked 5 to 10 days after injection, and chronic, spontaneously relapsing anemia persisted for 309 days.
51Cr labeling demonstrated decreased erythrocyte survival, i.e., a half-life of 8.4 days in cell wall-injected rats
versus 11.8 days in controls. Erythrocytes were mildly microcytic, and leukocyte counts were elevated during
early spontaneous reactivation of arthritis, 15 days after injection of peptidoglycan-polysaccharide. Bone
marrow myeloid/erythroid precursor ratios were elevated in arthritic rats (P < 0.0001). Purified peptidoglycan
produced an acute anemia lasting 10 days, while injection of group A streptococcal polysaccharide and
mutanolysin-digested cell wall did not affect the hematocrit. The minimal effective dose of peptidoglycan-
polysaccharide was 5 ,ug of rhamnose per g (body weight). Serum iron and transferrin levels were decreased
in cell wall-injected rats (P < 0.005) and were closely correlated with hematocrit values and joint inflammatory
scores. Stainable iron was increased in the liver, spleen, and mesenteric lymph nodes and unchanged in the
bone marrow of cell wall-injected rats. Anemia accompanying chronic, relapsing systemic inflammation
induced by peptidoglycan-polysaccharide polymers appears to be an excellent animal model of the anemia of
chronic disease.
Mild nonprogressive anemia accompanies chronic inflam-
mation of diverse etiologies, including chronic bacterial and
fungal infections (42), rheumatoid arthritis (43), Crohn's
disease (10), and widespread malignancies (13). The anemia
of chronic disease (inflammation) is characterized by mildly
decreased circulating erythrocyte (RBC) survival, lack of an
appropriate bone marrow compensatory response, and dis-
ordered iron kinetics (13, 24, 48). Typically, the serum iron,
total iron-binding capacity (TIBC), and marrow sideroblasts
are decreased in spite of normal-to-increased bone marrow
and tissue iron stores. Recent studies have suggested that
monokines secreted by activated macrophages may be re-
sponsible for suppression of bone marrow erythroid precur-
sors (33, 37). Anemia accompanies several experimental
inflammatory states associated with macrophage activation,
including adjuvant arthritis (25), arthritis induced by viable
BCG (26) and Mycoplasma arthritidis (11), and turpentine
abscesses (32). These experimental models have been pro-
posed as animal models of the anemia of chronic inflamma-
tion, however, none of the models produce protracted ane-
mia nor exactly reproduce the bone marrow suppression and
disordered iron metabolism found in the anemia of chronic
disease (48).
Bacterial cell wall polymers induce well-characterized
acute and chronic granulomatous inflammation in a variety
of organs after local and systemic injection (35, 41). Pepti-
doglycan-polysaccharide (PG-APS) polymers derived from
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group A streptococci induce an acute and chronic systemic
inflammatory response characterized by hepatic granulomas
(20, 47) and spontaneously relapsing arthritis (8) that can
persist at least 1 year after a single intraperitoneal (i.p.)
injection into susceptible rat strains. Macrophages are acti-
vated to secrete increased amounts of interleukin-1 (IL-1) by
both in vitro and in vivo exposure to PG-APS (L. A. Bristol
and J. H. Schwab, submitted for publication).
This study is designed to determine whether a single i.p.
injection of PG-APS would produce protracted anemia and
to determine whether this well-characterized and reproduc-
ible chronic, systemic inflammatory response in genetically
susceptible rats could serve as a reliable model of the anemia
of chronic disease. We demonstrate that PG-APS produces a
chronic, spontaneously relapsing anemia that persists at
least 10 months after a single i.p. injection and whose course
closely parallels activity of peripheral arthritis. PG is the
moiety of PG-APS responsible for the anemia and arthritis.
PG-APS-induced anemia resembles human anemia of
chronic disease in the following respects: it is mild to
moderate, RBC survival is decreased, RBCs are slightly
microcytic, serum iron and transferrin concentrations are
decreased, and reticuloendothelial iron stores are normal or
increased.
(A portion of this work was presented as a poster at the
87th Annual Meeting of the American Society for Microbi-
ology in Atlanta, Ga., 1 to 6 March 1987, and was published
as an abstract [R. B. Sartor, S. K. Anderle, W. J. Cromar-
tie, and J. H. Schwab, Abstr. Annu. Meet. Am. Soc. Micro-
biol. 1987, B-146, p. 49].)
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MATERIALS AND METHODS
Animals. Female inbred Lewis rats were purchased from
Charles River Breeding Laboratories, Inc., Wilmington,
Mass., and were housed 2 or 3 per cage with free access to
Purina rat chow and water at all times. Rats weighed 140 to
160 g at the time of injection.
Cell wall polymer preparation. PG-APS polymers were
isolated under aseptic conditions from the cell walls of strain
D58 of group A streptococci (Streptococcus pyogenes) as
previously described in detail (40). Briefly, streptococci
grown in Todd-Hewitt broth (BBL Microbiology Systems,
Cockeysville, Md.) were disrupted in a Braun MSK cell
homogenizer (Bronwell Scientific, Inc., Rochester, N.Y.),
and the cell wall fraction was separated by filtration and
centrifugation. The cell walls were extracted three times in
2% sodium dodecyl sulfate (Sigma Chemical Co., St. Louis,
Mo.) at 56°C and then washed extensively and dialyzed to
remove the sodium dodecyl sulfate. Purified PG-APS poly-
mers (400 mg) were suspended in 20 ml of sterile phosphate-
buffered saline (PBS) (pH 7.2) and sonicated for 35 min using
a 0.5-in. (1.27-cm) probe and a setting of 8 (model 350;
Branson Sonic Power Co., Danbury, Conn.). The suspen-
sion was centrifuged at 10,000 x g for 30 min to remove large
particles. PG-APS fragments prepared by this method have
molecular weights ranging from 5 x 106 to 5 x 108 (16).
Sterility was confirmed by culturing 0.1 ml on sheep blood
agar. PG-APS concentrations for injections were calculated
on the basis of rhamnose values determined by the method
of Dische and Shettles (9). Immediately before injection,
PG-APS was diluted to appropriate concentrations in PBS
(pH 7.2) and sonicated for 3 min with a 9-kilocycle Sonic
oscillator (Raytheon Co., Waltham, Mass.) to disperse ag-
gregates.
Preparation of PG-APS fractions. Group-specific APS and
PG were prepared by hot formamide treatment of cell walls.
APS was purified from the supernatant by the method of
Krause (22), as modified by Chetty et al. (4), and contained
47% rhamnose. PG was purified by multiple formamide
extractions by the method of Krause and McCarty (23) and
contained 0.5% rhamnose.
Mutanolysin-digested PG-APS was prepared by a modifi-
cation of the method of Chetty et al. (5). The M-1 fraction of
mutanolysin, an endo-N-acetylmuramidase derived from
Streptomyces globisporus, was obtained from Miles Labo-
ratories, Inc., Elkhart, Ind. Samples (8 ml) of sonicated
PG-APS (27.4 mg of rhamnose) were diluted with 12 ml of
PBS containing 0.5 M sodium citrate and 0.05 mM MgCl2
containing 3.29 mg of mutanolysin and then incubated at
37°C with constant mixing for 11 h. The optical density
measured at 600 nm decreased from 0.492 to 0.135 after
incubation with mutanolysin. Mutanolysin-digested PG-APS
has previously been shown to have a molecular weight of <5
x 106 and to produce only transient edema without arthritis
upon i.p. injection (5).
Labeling of erythrocytes with -5Cr. RBCs from Lewis rats
were labeled in vitro with 51Cr as previously described (34).
51Cr-labeled RBCs were diluted to 1.07 x 10' cpm/ml in PBS
and injected within 30 min.
Experimental design. Lewis rats were injected i.p. with 1
ml of PG-APS or cell wall fraction diluted with PBS (pH 7.2)
to the appropriate concentration (rhamnose concentrations
cited in individual experiments). In each experiment, control
rats were injected i.p. with 1 ml of PBS. In the study
measuring RBC survival, 0.5 ml of 51Cr-labeled RBCs (5.35
x 105 cpm) was injected intravenously 30 min before i.p.
injection of PG-APS or PBS. Serial determinations of hema-
tocrit (HCT), 51Cr counts per minute, or sedimentation rates
were obtained at intervals outlined in individual experiments
from blood derived from transection of the tip of the tail. A
minimal volume of blood was obtained to prevent iron
deficiency. Bleeding was controlled by digital pressure on
the tail above the transection and by cauterization immedi-
ately after blood collection. Blood was collected directly into
two heparinized 75-mm-long microhematocrit capillary
tubes (approximately 70 [LI of operational volume; Fisher
Scientific, Pittsburgh, Pa.) for duplicate HCT and sedimen-
tation rate determinations and into heparinized microcentri-
fuge tubes (approximately 200-pL volume) for 51Cr or auto-
mated cell counting. Serum for iron and transferrin levels
was obtained at necropsy by cardiac puncture. All injections
and blood collections were done under ether inhalation
anesthesia to minimize discomfort, and animals were killed
by CO2 overdose.
Measurement of laboratory and clinical parameters. HCT
values were determined in duplicate microhematocrit tubes
immediately after centrifugation at 12,600 x g for 3 min.
Spontaneous sedimentation of RBCs was measured in mi-
crohematocrit capillary tubes allowed to stand upright for 30
min after collection at room temperature. The percent
plasma relative to total volume was read with a microhema-
tocrit capillary tube reader (Lancer, Brunswick Co., St.
Louis, Mo.). The amount of 51Cr within 0.1 ml of heparin-
ized blood was determined in a gamma counter (1197 series;
Automatic Gamma Counting System; Searle Analytic, Inc.,
Des Plains, Ill.). Counts per minute at each time point were
corrected for the spontaneous decay in 51Cr activity (phys-
ical half-life, 27.7 days). An automated cell counter (150
series; Baker Instruments Corp., Allentown, Pa.), pro-
grammed for rat blood cells, was used for hemoglobin, RBC
and leukocyte (WBC) counts, and mean corpuscular volume
determinations. Transferrin was measured immunoturbidi-
metrically (31) with the following modifications. Rat sera
were diluted 1:25 with PBS. Rabbit anti-rat transferrin
antiserum (Nordic Immunological Reagents, El Toro, Calif.)
was diluted 1:50 with 40 g of polyethylene glycol per liter of
PBS. Within-run imprecision for the transferrin assay was
less than 5%. The iron concentration was determined by
using Beckman's ferrozine method (Beckman Instruments,
Inc., Brea, Calif.) by the instructions of the manufacturer.
The analytical imprecision for the iron assay was less than
4%. The determinations of transferrin and iron were per-
formed on the Cobas-BIO centrifugal analyzer (Roche Ana-
lytical Instruments Inc., Nutley, N.J.). Iron stains were
performed on femoral bone marrow touch preparations and
Formalin-fixed liver and spleen sections by the method of
Gomori (18). Bone marrow myeloid/erythroid precursor
ratios were performed on touch preparations of femoral
marrows, which were stained with Wright's-Giemsa re-
agents. Bone marrow cellularity was determined in Forma-
lin-fixed decalcified femurs, sternums, and ankle joints
stained with hematoxylin and eosin. Arthritis was measured
by using a clinical joint score of 0 to 4+ for each ankle
(maximum score, 16) (8). We have previously demonstrated
a close correlation of clinical joint scores with radiographic
(6) and histologic (8) assessments of joint inflammation.
Statistical evaluation. Mean values of each experimental
parameter were calculated for each group of rats and com-
pared by Student's unpaired t test. Experimental parameters
were correlated by linear regression analysis.
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FIG. 1. Acute and chronic anemia and arthritis induced by PG-APS polymers derived from group A streptococci. Sterile, sonicated
PG-APS (20 jig of rhamnose per g) or PBS was injected i.p. into 10 female Lewis rats per group. Serial determinations ofHCT were measured
from blood collected in duplicate microcapillary tubes after transection of the tail. Joint scores were measured clinically as specified in the
text. The joint score of PBS-injected rats was 0 (scores not shown). SEM, Standard error of the mean; SD, standard deviation.
RESULTS
Time course of anemia and arthritis. Serial HCTs were
measured in female Lewis rats injected with PG-APS (20 ,ug
of rhamnose per g) or PBS. PG-APS-injected rats developed
a transient increase in HCT 17 h after injection, followed by
a protracted anemia compared with the PBS-injected control
group (Fig. 1). The time course of anemia followed a typical
pattern in this and subsequent experiments. An acute drop in
HCT occurred by 3 days after injection, with the lowest
HCT values (36.2% in the PG-APS group versus 45.1% in the
control group [P < 0.0001]) recorded 10 days after injection.
Over the next week, the HCT slowly increased but never
reached control values. Between 3 and 5 weeks after injec-
tion, individual rats developed a spontaneous recurrence of
persistent anemia. The peak of the chronic anemia at this
dose ofPG-APS occurred 49 days after injection (HCT value
of 36.4% ± 2.8% versus 46.5% ± 1.1% in the control group,
[P < 0.0001]). HCT values in the PG-APS-injected rats were
significantly lower than those of PBS-injected controls for
309 days after injection. Arthritis, as measured by the
clinical joint score, demonstrated a similar acute phase,
which peaked 3 days after PG-APS injection, and a chronic,
spontaneously relapsing phase beginning 4 weeks after in-
jection (Fig. 1). Mean values obscure the occasional dra-
matic change in the HCT and joint scores of individual rats
during the spontaneous relapses and remissions of anemia
and arthritis. The sporadic nature of the recurrence of
anemia led to relatively high standard deviations of HCT
values 3 to 4 weeks after injection (Fig. 1). All rats injected
with PG-APS abruptly developed recurrent anemia (HCT of
s40% and a decrease in HCT by >3 percentage points
within 1 week); 57% (4 of 7) had a reactivation of arthritis
within 1 week of the sudden drop in HCT. Recurrent anemia
preceded or accompanied spontaneous reactivation of arthri-
tis, which in the Lewis rat persists indefinitely as an anky-
losed joint with massive bony proliferation (20). Control rats
injected with PBS developed neither anemia nor arthritis.
RBC survival. Survival of syngeneic RBCs labeled in vitro
with 51Cr was compared in rats injected with PG-APS (20 ,ug
of rhamnose per g [body weight]) or PBS. PG-APS-injected
rats had significantly lower counts per minute per 100 RI of
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FIG. 2. RBC survival following PG-APS or buffer injection.
Shown are serial measurements of 51Cr activity in heparinized blood
following intravenous injection of syngeneic RBCs (5.35 x i05 cpm)
labeled in vitro 30 min before the i.p. injection of PG-APS (20 jig of
rhamnose per g) or PBS into groups of 10 female Lewis rats (the
same rats were used in Fig. 1). Results are corrected for the
spontaneous decay of 51Cr activity. SEM, Standard error of the
mean.
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TABLE 1. Ability of PG-APS constituents to induce anemia
Material HCT" (%) (mean ± SEM) on day:
injected 1 6 10 14 55
PG-APSb 45.6 ± 0.5* 40.5 ± 0.4** 41.6 ± 0.7* 42.3 ± 0.7* 44.5 ± 2.1
PG-APS digestc 43.7 ± 0.4 43.0 ± 0.6 44.2 ± 0.6 43.2 ± 0.7 46.5 ± 0.3
PGd 41.1 ± 0.6* 38.3 ± 0.9** 42.2 ± 0.8* 43.5 ± 0.8 46.9 ± 0.6
APSe 44.2 ± 0.6 42.6 ± 0.4 45.1 ± 0.6 44.8 ± 1.2 46.8 ± 0.2
PBSf 43.5 ± 0.4 44.0 ± 0.6 45.2 ± 0.7 44.7 ± 0.4 48.1 ± 0.2
a * for P < 0.01 compared with the PBS-injected group; **, P < 0.001 compared with the PBS-injected group.
b PG-APS polymers from group A streptococci (30 ,ug of rhamnose; approximately 90 ,ug [dry weight] of PG-APS per g [body weight]) injected i.p. into six
female Lewis rats.
c PG-APS polymers from group A streptococci (30 p.g of rhamnose per g [body weight]) predigested for 12 h with mutanolysin and then injected i.p. into six
rats.
d Purified PG (45 p.g [dry weight]/g [body weight]) injected i.p. into six rats.
e Formamide-extracted group A streptococcal APS (30 p.g of rhamnose per g [body weight]) injected i.p. into six rats.
f PBS injected i.p. into six rats (buffer control).
and extending until 51Cr was no longer detectable (Fig. 2).
The calculated half-life of blood cells, based on four half-
lives, was 8.4 days in the PG-APS-injected rats compared
with 11.8 days in controls. There was no evidence of
gastrointestinal blood loss by Hemoccult (Smith-Kline Diag-
nostics, Sunnyvale, Calif.) testing of fecal samples and no
evidence of bleeding from the cauterized tails. These results
demonstrate a moderate decrease in RBC survival in PG-
APS-treated rats which was not due to bleeding.
Active moiety of PG-APS. To determine which portion(s)
of the PG-APS polymer was responsible for protracted
anemia, we measured HCTs of rats injected with equivalent
high doses of purified PG and APS as well as enzymatically
degraded PG-APS (Table 1). As described above, rats in-
jected with nondigested PG-APS polymers developed acute
and chronic anemia and arthritis after a transient increase in
HCT 1 day after injection. Rats injected with PG had
arthritis and significantly decreased HCTs from 1 to 10 days
after injection, with peak anemia at 6 days, but no evidence
of chronic anemia or arthritis. In contrast, rats injected with
APS or mutanolysin-digested PG-APS did not demonstrate
decreased HCT values or arthritis at any time point but did
develop transient peripheral edema 30 min after injection as
previously described (4, 5). PG-injected rats did not develop
edema, but four of six rats had clinically detectable diarrhea,
and all six had conjunctivitis.
Dose response. Rats were injected with PG-APS in doses
ranging from 0 to 40 p.g of rhamnose per g (body weight) to
determine the minimally effective dose that produced acute
and chronic, relapsing anemia (Table 2). Rats injected with
0.5 or 1 p.g of rhamnose per g (body weight) did not develop
clinically significant anemia at any time, although sporadic
time points showed a small but statistically significant differ-
ence in HCT compared with control values. PG-APS in
doses between 10 and 40 p.g of rhamnose per g (body weight)
induced acute anemia peaking at 4 to 7 days after injection in
a dose-dependent fashion. Rats injected with 5 to 40 ,ug of
rhamnose developed chronic, spontaneously relapsing ane-
mia with very interesting differences in the timing of the
recurrences, depending on the dose injected (Table 3). Rats
receiving 5 ,ug/g (body weight) i.p. had no acute change in
HCT but developed chronic anemia 35 to 113 days after
injection. Only one rat in this group had spontaneous reac-
tivation of anemia. Rats receiving 10 to 20 I.g of rhamnose
per g (body weight) developed recurrent, chronic anemia
which, in most animals, never returned to normal levels.
These rats developed a recurrence of moderate (HCT of
<40%) anemia 18 to 28 days after PG-APS injection; the
second and third recurrences of anemia occurred 50 to 113
days after injection. In contrast, HCTs of rats receiving the
highest dose of PG-APS (40 jig of rhamnose per g [body
weight]) returned to completely normal levels by 10 days
after injection and remained no different than control levels
until 70 days after injection (Tables 2 and 3). Eventually, five
of nine rats injected with 40 jig of rhamnose PG-APS per g
(body weight) developed moderate chronic anemia, but none
had a second relapse during the 135-day observation period.
Iron and transferrin levels. To determine whether iron
metabolism was abnormal during chronic inflammation in-
duced by PG-APS, serum iron and transferrin levels were
TABLE 2. Anemia with increasing doses of PG-APS polymers
PG-APS HCTb (%) (mean ± SEM) on day:
dose 7 14 22 50 113
0 44.3 ± 0.3 47.8 ± 0.2 46.0 ± 0.3 48.6 ± 0.3 47.3 ± 0.6
0.5 43.2 ± 0.4 46.5 ± 0.3* 46.0 ± 0.6 48.1 ± 0.4 47.3 ± 0.5
1 43.6 ± 0.5 46.8 ± 0.6 45.8 ± 0.3 47.5 ± 0.2* 46.4 ± 0.3
5 44.4 ± 0.3 46.8 ± 0.5 45.8 ± 0.3 43.9 + 1.9 42.1 ± 1.2*
10 42.9 ± 0.4* 43.7 ± 0.8** 40.2 ± 1.9* 43.9 ± 1.9 42.9 ± 0.9*
15 40.9 ± 0.8** 39.8 ± 1.3** 35.3 ± 1.6** 43.6 ± 1.2* 42.6 ± 0.5**
20 41.9 ± 0.9* 42.2 ± 1.4* 39.0 ± 2.5 43.6 ± 1.2* 43.5 ± 1.1*
40 39.6 ± 0.8** 46.0 + 0.3** 45.9 ± 0.4 48.7 ± 0.3 38.9 ± 1.5**
" PG-APS polymers from group A streptococci injected i.p. into six to nine female Lewis rats per group. Values are in micrograms of rhamnose per gram (body
weight).
b *, P < 0.02 compared with rats given no PG-APS; **, P < 0.001 compared with rats given no PG-APS.
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TABLE 3. Incidence and timing of severe anemia
(HCT of <40%) with increasing doses of PG-APS
Chronic anemia
PG-APS Acute anemia
dose' Recurrence 1 Recurrence 2
No.b Peak" No. Peak No. Peak
0 0 0 0
0.5 0 0 0
1.0 0 0 0
5 0 5/8 35-113 1/8 70
10 0 5/9 22-28 5/9 63
15 4/7 7 7/7 22 4/7 63-70
20 5/9 7-10 7/9 18-22 3/9 63-70
40 5/7 4 5/9 70-113 0
a See footnote a of Table 2.
b Number of rats with anemia/number of rats injected.
' Peak occurrence of anemia. Values shown are days after i.p. injection of
PG-APS.
measured 36 days after i.p. injection of PG-APS (15 ,ug of
rhamnose per g [body weight]). PG-APS-injected rats had
significantly lower iron and transferrin levels than buffer-
injected control rats (Table 4), despite one misinjected rat in
the PG-APS group which did not develop arthritis, anemia,
or abnormal iron and transferrin levels.
Bone marrows of rats injected with PG-APS 15 days prior
to sacrifice contained normal concentrations of intracellular
iron by cytochemical staining. By 33 and 65 days after
injection, iron staining within the bone marrow was dimin-
ished compared with iron staining in controls but remained
detectable. Iron-containing macrophages were markedly in-
creased in livers of rats injected with PG-APS, with intensely
staining enlarged macrophages concentrated at the periphery
of hepatic granulomas (Fig. 3), portal tracts, and central
veins. Kupffer cells of PG-APS-injected rats frequently
contained detectable iron and were randomly distributed. In
contrast, livers of control rats had rare Kupffer cells con-
taining faintly staining iron, which were usually adjacent to
central veins. Mesenteric lymph nodes and spleens of PG-
APS-injected rats contained increased numbers of iron-
containing macrophages, frequently present in aggregates
and giant cells.
Correlation of experimental parameters. PG-APS-injected
rats which developed anemia consistently displayed concur-
rent arthritis, increased RBC sedimentation rates, hepatic
granulomas, and decreased serum iron and transferrin levels
(Table 4). There was a striking temporal relationship be-
s W.f
'A I s; b .
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FIG. 3. Iron-laden macrophages within a hepatic granuloma. A
female Lewis rat was injected i.p. with PG-APS polymers (30 ,ug of
rhamnose per g) 65 days before necropsy. This small granuloma in
the hepatic parenchyma near a central vein contains macrophages
with densely staining iron by the method of Gomori (18). Magnifi-
cation, x450).
tween arthritis and delayed onset or recurrent anemia (Fig.
4) as well as between the acute phase of inflammation and
anemia (Fig. 1). In pooled experiments, 35 of 39 (90%) rats
which developed recurrent anemia had their first reactiva-
tion of arthritis within 1 week of the abrupt drop in HCT. At
four time points between 10 and 36 days after injection of
PG-APS or PBS, HCT and joint scores were very closely
correlated, with r values ranging from -0.93 to -0.98 and P
< 0.0001. Owing to variability in the timing of spontaneously
reactivating inflammation within an experimental group,
mean values did not adequately demonstrate the close cor-
relation that existed between HCT values and joint scores
during recurrence of arthritis and anemia in individual rats
(Fig. 4). Lewis rats develop irreversible destructive arthritis
TABLE 4. Correlation of experimental parameters in cell wall-injected and control rats
Mean" + SEM
Material injected
or correlation . Serum RBCcoefficient HCT (%) Serum Iron transferrin sedimentation Joint score
(jig/dI) ~~(mgldl)(%
Material injected
PG-APSb 38.8 ± 2.7* 149 ± 49* 30.4 ± 12.9* 3.8 ± 1.3** 6.4 ± 1.6*
PBSC 47.7 ± 0.2 358 19 79.0 ± 1.5 0.2 ± 0.1 0 0
Correlation coefficient
HCT 0.97 0.97 0.87 0.98
Joint score 0.98 0.97 0.98 0.86
Transferrin 0.97 0.95 0.68 0.98
a *, p < 0.005 compared with PBS-injected rats; **, P = 0.01 compared with PBS-injected rats.
b PG-APS polymers (15 ,ug of rhamnose per g [body weight]) injected i.p. into five rats 36 days before sacrifice.
' PBS injected i.p. into five rats 36 days before sacrifice.
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FIG. 4. Temporal relationship between delayed onset of anemia
and arthritis in a female Lewis rat injected i.p. with PG-APS
polymers (5 ,ug of rhamnose per g). This rat did not develop anemia
or arthritis until 42 and 50 days, respectively, after injection of a low
dose of PG-APS. The anemia was maximal at the onset of arthritis.
with bony proliferation and ankylosis, leading to persistently
elevated joint scores because of ankle enlargement due to
new bone formation, but no gross evidence of active inflam-
mation was detected by edema and erythema. Anemia was
better correlated with active joint inflammation than rela-
tively inactive chronic joint destruction (Fig. 1) and usually
immediately preceded reactivation of arthritis in individual
rats (Fig. 4). Similarly, increased spontaneous sedimentation
of RBCs was associated with recurrence of anemia and
arthritis (Table 5) and returned to normal values during
remission of active inflammation.
Rats studied during the first spontaneous reactivation of
arthritis, 15 days after PG-APS injection, developed severe
anemia which was accompanied by significantly decreased
hemoglobin and RBC counts (P - 0.001, Table 6). The mean
corpuscular volume of the PG-APS-injected rats was slightly
lower than that for control rats. PG-APS-injected rats also
had elevated WBC counts, which were closely correlated
with HCT values (r = 0.93) and joint scores (r = 0.94). The
bone marrows of these rats had decreased numbers of RBC
precursors relative to WBC precursors, as demonstrated by
their significantly elevated bone marrow myeloid precursors/
erythroid precursor ratios (Table 6). Bone marrow histology
revealed normal-to-increased cellularity, with increased
numbers of megakaryocytes and granulocyte precursors, in
the PG-APS-injected rats compared with PBS-injected con-
trols.
DISCUSSION
Anemia associated with acute and chronic systemic in-
flammation induced by PG-APS has several unique features
which make it a useful model to study the anemia of chronic
inflammation. PG-APS-induced anemia was protracted, as it
persisted for at least 10 months after a single aqueous i.p.
injection, and spontaneously relapsed and remitted, with its
clinical course correlating with exacerbations and remissions
of arthritis. Anemia following bacterial lipopolysaccharide
(endotoxin) injection is transient and very mild (17). Forma-
lin-killed Corynebacterium parvum injected into mice (27),
infection with M. arthritides (11) or BCG (26), and footpad
injection of complete Freund adjuvant (25) induce anemia
which is monophasic, with no evidence of spontaneous
recurrence, and is limited to at most 8-weeks duration (26).
PG-APS is resistant to biodegradation (39) and persists
within macrophages for at least 4 months after injection (8,
35). Spontaneous reactivation of inflammation following a
single local or systemic injection of PG-APS is a character-
istic feature of inflammation induced by these phlogistic
complexes and may be due to slow intracellular degradation
of polymers with episodic release from tissue stores (14).
In the anemia of chronic disease, serum iron, transferrin,
and TIBC are low despite normal or increased bone marrow
and tissue iron stores (13, 24, 48). Rats injected with PG-APS
had significantly lower serum iron and transferrin concen-
trations in the chronic phase of inflammation compared with
those of control rats, and there was a strong correlation
between iron and transferrin levels and the activity of
arthritis. Macrophages within the liver, spleen, and mesen-
teric lymph nodes had increased stainable iron, particularly
within giant cells and granulomas. Fibrotic, more-advanced
hepatic granulomas had more densely staining iron than
recently formed, active granulomas with necrotic centers,
suggesting increased sequestration of iron with chronic
inflammation. Mice injected with Freund adjuvant have
slightly decreased plasma iron, but decreased TIBC and
transferrin saturation develop only late in the course of
anemia (25) and splenic iron is diminished, rather than
increased, after repeated injections of adjuvant (28). The
anemia secondary to BCG infection is not associated with
hypoferremia (26). Injection of C. parvum into rats leads to
a prompt decrease in serum iron and retention of iron within
mononuclear phagocytes but an increased plasma TIBC (3).
Similarly, mice with turpentine-induced inflammation (2) or
infected with M. arthritidis (11) have a prompt decrease in
plasma iron but an increase in transferrin and TIBC. Thus,
PG-APS-induced chronic anemia in rats more closely mimics
TABLE 5. HCTs, sedimentation rates, and joint scores during reactivation of PG-APS-induced inflammation
PG-APS-injected rats" PBS-injected rats
Rat no.
or mean HCT (%) Sedimentation Joint score HCT % Sedimentation Joint scorerateb ~~~~~~~~~~~~~~~~rate
1 36 15 8 47.5 0.5 0
2 47.5 0.5 0 48 0.5 0
3 28.5 10 8 49 1 0
4 31.5 24 4.5 48.5 0.5 0
5 30 36 7 48.5 0.5 0
Mean + SEM 34.7 ± 3.4' 17.1 + 6.1" 5.5 ± 1.5' 48.3 ± 0.3 0.6 ± 0.1 0
a Values measured 21 days after i.p. injection of PG-APS (15 ,ug of rhamnose per g [body weight]).
b Spontaneous sedimentation of RBC measured as percentage of total capillary tube volume 30 min after collection.
Pp < 0.003 compared with PBS-injected rats.
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TABLE 6. Blood and bone marrow parameters during the first reactivation of PG-APS-induced arthritis
Mean ± SEM"
Material
injected" HCT t Hemoglobin No. of RBC MCV' No. of WBC Bone marrow myeloid
(g/dl) (106/mm3) (tim3) (103/mm3) precursor/erythroid
precursor ratio
PG-APS 33.7 ± 2.9* 11.5 ± 0.9* 5.73 + 0.42* 58.7 ± 1.5** 38.5 ± 6.0* 3.4 ± 0.5*
PBS 47.7 ± 0.7 16.2 ± 0.2 7.65 ± 0.12 62.4 ± 0.7 6.9 ± 0.7 0.8 ± 0.2
a Values measured 15 days after i.p. injection of PG-APS (15 ,ug of rhamnose per g [body weight]) or PBS (1 ml) during the first spontaneous reactivation of
arthritis.
b Values shown are the mean for five rats per group. *, P < 0.001 compared with PBS-injected rats; **, P = 0.03 compared with PBS-injected rats.
' Mean corpuscular volume, calculated by HCT/RBC.
the clinical abnormalities of iron metabolism found in the
anemia of chronic disease than previously described models
of chronic inflammation or infection.
The demonstration that the PG fraction induced anemia is
consistent with previous observations that polymeric PG is
the active moiety responsible for most inflammatory reac-
tions induced by PG-APS fragments from a variety of
bacterial species (20, 41). Digestion of PG by the murami-
dase, mutanolysin, abrogates acute and chronic arthritis (20)
and prevents acute vascular permeability changes in the
gut-associated lymphoid tissue induced by PG-APS (R. B.
Sartor, unpublished data). Purified PG is readily degraded by
lysozyme, in contrast to PG covalently bound to APS (1).
This observation is consistent with the transient anemia and
arthritis which resolved by 14 days after injection of isolated
PG with no evidence of recurrence, while PG-APS produced
protracted, spontaneously relapsing anemia and arthritis.
Purified group A streptococcal APS produced transient
peripheral edema, as previously described (4), but no anemia
or chronic arthritis.
The mechanism of anemia induced by PG-APS is un-
known but probably involves both decreased RBC survival
and synthesis. The rapid decrease in HCT during the acute
phase and spontaneous recurrence of anemia, combined
with the slightly decreased RBC half-life measured by 5"Cr
labeling, indicates that RBC survival is diminished. There
was no evidence of gastrointestinal or external loss of RBCs,
and the purified PG-APS preparation used for these studies
did not contain streptococcal hemolysin. Patients with rheu-
matoid arthritis have a 20% decrease in RBC survival (43),
and rats with adjuvant arthritis have a circulating 51Cr-RBC
half-life of 10.2 days compared with 13.4 days in controls
(28). One mechanism of shortened RBC survival is phago-
cytosis of RBCs by reticuloendothelial cells, which occurs in
C. parvum-treated mice (27). Splenic macrophages normally
clear senescent RBCs from the circtilation. Macrophages in
the spleen, liver, bone marrow, and lymph nodes can phago-
cytose R13Cs that have subtle membrane damage or are
coated with antibody or complement (7). Activation of
macrophages is a common feature of many types of inflam-
mation and has been postulated to be important in the
pathogenesis of the anemia of chronic disease (24, 33, 37).
PG-APS activates macrophages in vitro and in vivo (39;
Bristol and Schwab, submitted), and intravenous injection of
PG-APS leads to phagocytosis of RBCs by macrophages
within mesenteric lymph nodes (34). PG activates comple-
ment (12), and Pryzwansky et al. (30) have demonstrated in
vitro aggregation of RBCs and phagocytic cells via PG-
APS-complement (C3b) bridging. Erythrophagocytosis by
activated reticuloendothelial cells could explain increased
stainable iron within macrophages of the liver, spleen, and
mesenteric lymph nodes of PG-APS-injected rats with ane-
mia. Another possible explanation of increased macrophage
iron is sequestration of lactoferrin-iron complexes after
liberation of lactoferrin from the secondary granules of
PG-APS-activated polymorphonuclear leukocytes.
The primary defect in the anemia of chronic disease
appears to be the lack of an appropriate bone marrow
response to the slight decrease in RBC survival (13, 48).
Figure 2 shows only a slightly increased destruction of RBCs
during the relatively abrupt recurrence of anemia 3 to 5
weeks after PG-APS injection, indicating variable suppres-
sion of RBC synthesis during different phases of experimen-
tal inflammation. Activated macrophages have been shown
to suppress erythropoiesis both during stimulation with LPS
(36, 37) or in disseminated histoplasmosis infection (50).
Mouse peritoneal macrophages activated by human recom-
binant tumor necrosis factor or Cryptococcus neoformans
infection suppress erythroid progenitor cell growth (33). Lee
(24) speculated that IL-1 mediates the anemia of chronic
disease, but it is apparent that IL-1 has no direct erythroid
inhibitory effect (21, 33, 37), although this monokine acti-
vates polymorphonuclear leukocytes to release lactoferrin,
causes a decrease in serum iron (24), and is produced by
scattered bone marrow cells (44). IL-1 has indirect regula-
tory effects on hematopoiesis by stimulating bone marrow
stromal cells (15), T lymphocytes (19), fibroblasts (21), and
endothelial cells (38) to release multilineage hematopoietic
growth factors and activating fibroblasts to release soluble
factors that regulate early hematopoietic progenitor cells
(51). Thus, IL-1 may be responsible for the leukocytosis
observed after PG-APS injection. Recently, Tracey et al.
(46) demonstrated that twice-daily administration of tumor
necrosis factor to rats for 8 days induced a progressive
anemia which appeared within 3 days and was associated
with a leukocytosis. We postulate that the chronic anemia
induced by PG-APS is a result of peptidoglycan activation of
macrophages which liberate monokines, including tumor
necrosis factor (45) and IL-1 (Bristol and Schwab, submit-
ted), and soluble inflammatory mediators, such as prosta-
glandin E2 (49), which may suppress erythropoiesis directly
or indirectly. Alternatively, stimulated T cells, which have
been implicated in the pathogenesis of PG-APS-induced
inflammation (47), may suppress the bone marrow, as has
been demonstrated in rheumatoid arthritis (43) and BCG
infection in mice (29).
PG-APS-induced inflammation in rats provides an excel-
lent model for examining protracted, spontaneously relaps-
ing anemia with modestly decreased RBC survival and
altered iron metabolism associated with well-characterized
arthritis. PG-APS is chemically and antigenically defined and
can activate macrophages in vivo or in vitro, permitting
more thorough evaluation of mechanisms of bone marrow
suppression. Activation of macrophages by PG-PS may be a
common mechanism of the anemia accompanying chronic
infection by many bacterial species.
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